ClearPoint Neuro, Inc. announced multiple key milestones demonstrating significant progression within its Biologics and Drug Delivery Portfolio. These advancements underscore the company's growing role in the neuro-therapy landscape.
A major highlight includes the performance of the first commercial treatments for KEBILIDI™ (eladocagene exuparvovec-tneq) in the United States, utilizing the company's SmartFlow® Neuro Cannula. KEBILIDI™ is a gene therapy approved for pediatric and adult patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Further strengthening its position, ClearPoint Neuro reported that additional partners have been accepted for expedited review pathways, and new cell and gene infusion ICD-10 codes have been created. The company also achieved a record number of clinical trial patients treated globally in the month of July, indicating accelerating adoption and progress in its partner programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.